Inkoop van eigen aandelen

The main market mechanism here is technical, not fundamental: a steady issuer bid in a relatively illiquid biotech can compress free float and create an incremental floor under the stock, especially when the tape is already range-bound. That matters more for LKFT than for large-cap peers because marginal demand can move the last traded price, but it should not be confused with a change in clinical probability or pipeline NPV.

Second-order, this is a signal on capital allocation discipline. For biotech holders, buybacks usually imply management sees no imminent need to preserve every euro for external growth, which can help the multiple if investors already view the balance sheet as overcapitalized. The flip side is that if the core asset base disappoints, the market may later punish the decision to recycle cash into repurchases instead of preserving optionality for BD, licensing, or a higher burn period.

Time horizon matters: over days, this can support the stock mechanically; over 1-3 months, the key question is whether the program remains active enough to offset normal selling from event-driven biotech owners. Over 6-18 months, valuation will revert to pipeline data, but the buyback may reduce downside volatility and improve relative performance versus XBI/IBB if no major clinical catalyst is near.

Contrarian view: the consensus will read this as bullish confidence, but the more useful interpretation is that management sees limited near-term internal uses for capital. If repurchases slow, if cash burn rises, or if the next development update is delayed, this support vanishes quickly. The move is mildly supportive, but likely overinterpreted if investors expect a rerating absent a real data catalyst.